Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients
A Pilot Study of Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients Who Can Tolerate Aggressive Therapy
Status: Enrolling
Updated:  10/5/2015
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients
A Pilot Study of Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients Who Can Tolerate Aggressive Therapy
Status: Enrolling
Updated: 10/5/2015
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Imaging in MGUS, SMM and MM
A Pilot Study of Novel Imaging Modalities in Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), and Multiple Myeloma (MM)
Status: Enrolling
Updated:  10/5/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Imaging in MGUS, SMM and MM
A Pilot Study of Novel Imaging Modalities in Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), and Multiple Myeloma (MM)
Status: Enrolling
Updated: 10/5/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
An Observational Cohort Study on Transplant-Related Mortality in Patients Receiving Either a Hematopoietic Stem Cell Transplantation Without ATIR or an Umbilical Cord Blood Transplantation
Status: Enrolling
Updated:  10/5/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
An Observational Cohort Study on Transplant-Related Mortality in Patients Receiving Either a Hematopoietic Stem Cell Transplantation Without ATIR or an Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 10/5/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
An Observational Cohort Study on Transplant-Related Mortality in Patients Receiving Either a Hematopoietic Stem Cell Transplantation Without ATIR or an Umbilical Cord Blood Transplantation
Status: Enrolling
Updated:  10/5/2015
Algemeen Ziekenhuis Sint-Jan
mi
from
Brugge,
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
An Observational Cohort Study on Transplant-Related Mortality in Patients Receiving Either a Hematopoietic Stem Cell Transplantation Without ATIR or an Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 10/5/2015
Algemeen Ziekenhuis Sint-Jan
mi
from
Brugge,
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
Emory University Hospitals; Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
Emory University Hospitals; Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
Tulane University Hospital and Clinics
mi
from
New Orleans, LA
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
Tulane University Hospital and Clinics
mi
from
New Orleans, LA
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
University of Maryland Medical Center
mi
from
Baltimore, MD
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
Johns Hopkins Hospital
mi
from
Baltimore, MD
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
Children's Hospital Boston; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital
mi
from
Boston, MA
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
Children's Hospital Boston; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
NY-Presbyterian Hosp/Weill Cornell Medical Center
mi
from
New York, NY
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
NY-Presbyterian Hosp/Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
University Hospital of Cleveland
mi
from
Cleveland, OH
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
University Hospital of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
U of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
U of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
U of Pennsylvania Health System; Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
U of Pennsylvania Health System; Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
University of Pittsburgh Presbyterian and Shadyside Hospital
mi
from
Pittsburgh, PA
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
University of Pittsburgh Presbyterian and Shadyside Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
U of Texas SW Medical Center at Dallas
mi
from
Dallas, TX
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
U of Texas SW Medical Center at Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
Virginia Mason Hospital
mi
from
Seattle, WA
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
Virginia Mason Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
U of Washington Medical Center/FHCRC; Children's Hospital and Medical Center
mi
from
Seattle, WA
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
U of Washington Medical Center/FHCRC; Children's Hospital and Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
Oncology Alliance/St. Luke's Hospital
mi
from
Milwaukee, WI
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
Oncology Alliance/St. Luke's Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated:  10/5/2015
Froedtert Memorial Lutheran Hospital
mi
from
Milwaukee, WI
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Status: Enrolling
Updated: 10/5/2015
Froedtert Memorial Lutheran Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated:  10/5/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated: 10/5/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated:  10/5/2015
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated: 10/5/2015
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated:  10/5/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated: 10/5/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated:  10/5/2015
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated: 10/5/2015
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated:  10/5/2015
Children's Memorial Hospital, Chicago
mi
from
Chicago, IL
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated: 10/5/2015
Children's Memorial Hospital, Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated:  10/5/2015
Weill Medical College of Cornell
mi
from
New York, NY
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated: 10/5/2015
Weill Medical College of Cornell
mi
from
New York, NY
Click here to add this to my saved trials
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated:  10/5/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated: 10/5/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated:  10/5/2015
Baylor College of Medicine
mi
from
Houston, TX
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated: 10/5/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated:  10/5/2015
University Health Network - Toronto General Hospital
mi
from
Toronto,
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles
Status: Enrolling
Updated: 10/5/2015
University Health Network - Toronto General Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations
Status: Enrolling
Updated:  10/6/2015
Comprehensive Cancer Centers of Nevada CCC of Nevada (1)
mi
from
Las Vegas, NV
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations
Status: Enrolling
Updated: 10/6/2015
Comprehensive Cancer Centers of Nevada CCC of Nevada (1)
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations
Status: Enrolling
Updated:  10/6/2015
Cancer Center of the High Plains
mi
from
Amarillo, TX
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations
Status: Enrolling
Updated: 10/6/2015
Cancer Center of the High Plains
mi
from
Amarillo, TX
Click here to add this to my saved trials
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations
Status: Enrolling
Updated:  10/6/2015
Baylor Health Care System/Sammons Cancer Center Dept. of Sammons Cancer (2)
mi
from
Dallas, TX
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations
Status: Enrolling
Updated: 10/6/2015
Baylor Health Care System/Sammons Cancer Center Dept. of Sammons Cancer (2)
mi
from
Dallas, TX
Click here to add this to my saved trials
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated:  10/6/2015
Mayo Clinic Scottsdale-Phoenix
mi
from
Scottsdale, AZ
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated: 10/6/2015
Mayo Clinic Scottsdale-Phoenix
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated:  10/6/2015
Duke University Health System
mi
from
Durham, NC
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated: 10/6/2015
Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated:  10/6/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated: 10/6/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated:  10/6/2015
UT MD Anderson Cancer
mi
from
Houston, TX
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated: 10/6/2015
UT MD Anderson Cancer
mi
from
Houston, TX
Click here to add this to my saved trials
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated:  10/6/2015
Northwestern University
mi
from
Chicago, IL
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated: 10/6/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated:  10/6/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated: 10/6/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated:  10/6/2015
Universitätsklinikum Ulm
mi
from
Ulm,
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Enrolling
Updated: 10/6/2015
Universitätsklinikum Ulm
mi
from
Ulm,
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Cancer Care of Western North Carolina
mi
from
Asheville, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Cancer Care of Western North Carolina
mi
from
Asheville, NC
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
mi
from
Greensboro, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
mi
from
Greensboro, NC
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Leo W. Jenkins Cancer Center at ECU Medical School
mi
from
Greenville, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Leo W. Jenkins Cancer Center at ECU Medical School
mi
from
Greenville, NC
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Marion L. Shepard Cancer Center
mi
from
Washington, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Marion L. Shepard Cancer Center
mi
from
Washington, NC
Click here to add this to my saved trials
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
Status: Enrolling
Updated:  10/7/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
Status: Enrolling
Updated: 10/7/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials